“I no longer have any angina pain or shortness of breath; no symptoms whatsoever. I am walking 3 miles per day and lifting heavy weights again. I consider this a complete reversal.
Dusseldorf, Germany, (PRWEB) February 22, 2011
The XCell-Center, Europe’s leading stem cell therapy provider has released results from 24 moderate to severe ischemic heart disease patients treated with autologous bone marrow stem cells. Clinical improvements were observed in 80% of patients following treatment.
Post-treatment left ventricular ejection fraction (LVEF) increased an average of 24%. LVEF which measures the fraction of blood pumped out of the heart's left ventricle with each heart beat, is an important predictor of heart patient prognosis. Other general improvements included reduced medication, decreased shortness of breath, improved strength and endurance and reduced edema (swelling). These results are consistent with a number of clinical trials and studies published from around the world.
“I no longer have any angina pain or shortness of breath; no symptoms whatsoever. I am walking 3 miles per day and lifting heavy weights again. I consider this a complete reversal. I saw my cardiologist 2 weeks ago for more testing and he is still shaking his head!” exclaimed Aaron Wood five months after treatment. Mr. Wood was suffering from heart failure following three heart attacks and was treated at the XCell-Center’s Dusseldorf clinic in May 2009.
The stem cell heart treatment begins by collecting a small amount bone marrow from the patient’s hip bone using a thin needle under local anesthesia. The stem cells are then separated from the bone marrow at the XCell-Center’s EU certified cGMP laboratory (current good manufacturing process). Before the cells leave the lab, they are counted and their vitality is confirmed. The last step of the treatment is the minimally invasive implantation procedure, which consists of inserting a cardiac catheter into the patient’s right femoral artery and then guiding it to the heart where the stem cells are released into the coronary arteries.
The cost of the XCell-Center heart treatment is 13,500 Euros. Patients suffering from ischemic or non-ischemic cardiomyopathy who have a diminished left ventricular function may qualify for this life-changing treatment.
About the XCell-Center
The XCell-Center operates treatment centers in Cologne and Dusseldorf, Germany. It is the first clinic in Europe to specialize in regenerative medicine using autologous bone marrow stem cell therapy and operates in accordance with German law, European guidelines and ISO 9001. Its specialized medical team of German physicians includes specialists in: neurosurgery, orthopedics, cardiology, radiology, anesthesiology and pharmacology.
The XCell-Center also treats Diabetes and its complications (Erectile Dysfunction and Peripheral Artery Disease), Stroke, Cerebral Palsy, Autism, Spinal Cord Injuries, Orthopedic diseases, Heart Disease and degenerative diseases such as Multiple Sclerosis, CCSVI, Parkinson's, Alzheimer's and several eye diseases.
Since its inauguration in 2007, more than 4,000 patients have been treated.
For more information on Stem Cell Therapy:
at the Institute for Regenerative Medicine
Am Heerdter Krankenhaus 2
40549 Dusseldorf, Germany
Phone: 1-866-680-8202 (USA Toll-Free) (+49) 0221-802-5095 (Germany)
Fax: 1-713-583-9322 (USA) (+49) 0221-2921-2550 (Germany)